Lonza

💰 $445.7m Post-IPO Debt on 2023-11-06PharmaceuticalBiotechnologyLife Science
Website LinkedIn Email Phone # Facebook Twitter

Lonza Group AG is a leading Life Sciences driven chemical company that provides active ingredients, chemical intermediates, and biotechnology solutions for the pharmaceutical and agrochemical sectors. With a focus on custom manufacturing and biopharmaceuticals, Lonza operates in three main divisions: Exclusive Synthesis & Biopharmaceuticals, Organic Fine & Performance Chemicals, and Polymer Intermediates, offering a wide range of products and services including microbial fermentation, therapeutic monoclonal antibodies, and various organic chemicals.

Related companies: